Dr. William J. Gartland, Jr. 
April 18, 1988 
All things considered, there is no indication of hazard associated with 
the experiments and strain described in the Eli Lilly proposal. There is, 
however, an important economic benefit to be gained that is directly attri- 
butable to an application of recombinant DNA technology. I support the 
Eli Lilly proposal and urge that the NIH RAC approve it. 
Sincerely yours, 
Jack J. Manis, Ph.D. 
Associate Director 
Bioprocess R&D 
dac 
Recombinant DNA Research. Volume 13 
[357] 
